Subcutaneous versus intravenous trastuzumab for HER2-positive breast cancer: a global systematic review and meta-analysis with a cost-minimization analysis from the Chinese healthcare system perspective

BackgroundSubcutaneous (SC) trastuzumab offers a more convenient alternative to intravenous (IV) administration for HER2-positive breast cancer, potentially improving healthcare efficiency and patient experience. Although SC trastuzumab was approved in Europe in 2013 and in the United States in 2019...

Cijeli opis

Bibliografski detalji

Glavni autori:	Zheng Zeng, Li Zhong, Ling Zhu, Luqin Liao, Zefeng Zhu, Yuening Cao, Da Zheng, Guidong Huang, Wei Chen, Lin Zhang
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2026-01-01
Serija:	Frontiers in Pharmacology
Teme:	HER2-positive breast cancer intravenous administration patient preference subcutaneous injection systematic review trastuzumab
Online pristup:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1730175/full
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!